EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide1. Chemotherapies such as the topoisomerase II inhibitor (TopoIIi) etoposide effectively reduce disease in a minority of NSCLC patients2,3; therefore, alternative drug targets, including epigenetic enzymes, are...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393352/ |